Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCEH1 | Q6PIU2 | 6/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4672733 | 0.87 | ERN1 (0.43) | NCEH1LIMK2HSD17B2 | |
| SCHEMBL4672597 | 0.84 | PTPN1 (0.47) | NCEH1HTTPPARGPPARDPPARA | |
| SCHEMBL4670747 | 0.84 | NCEH1 (0.41) | NCEH1MCHR1HTTPPARGPPARD | |
| SCHEMBL4675886 | 0.75 | PTPN1 (0.46) | NCEH1PPARGPPARDPPARA | |
| SCHEMBL4672741 | 0.68 | PPARG (0.48) | NCEH1HTTPPARGPPARDPPARA | |
| SCHEMBL9007497 | 0.68 | CYP19A1 (0.49) | NCEH1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL11745958 | 0.67 | GAA (0.61) | NCEH1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL9007503 | 0.67 | NCEH1 (0.48) | NCEH1HTTPOLBSMN1; SMN2 | |
| Methane SCHEMBL10453459 | 0.66 | GAA (0.60) | NCEH1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL4673038 | 0.66 | NCEH1 (0.49) | NCEH1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1397341-B1 | 6-(ARYL-AMIDO OR ARYL-AMIDOMETHYL)-NAPHTHALEN-2-YLOXY-ACIDIC DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 (PAI-1) | WYETH CORP (US) | 2008-08-06 | — | — | EP | disclosed |
| US-6589970-B2 | This invention provides novel compounds, pharmaceutical compositions and methods of treating thrombotic disorders in mammals, the compounds having the formula: | WYETH | 2003-07-08 | — | — | US | disclosed |
| US-20030045560-A1 | 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | WYETH | 2003-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045560-A1 | 6-(Aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) | SERPINC1, F11, SERPINE1 | NCEH1 86/4885MCHR1 1603/4885HTT 313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.